Literature DB >> 1035504

Interactions of antiestrogens with human breast cancer in long-term tissue culture.

M Lippman, G Bolan, K Huff.   

Abstract

A variety of antiestrogens can be shown to antagonize estrogen action in animal model systems. Several of these compounds are useful in the management of metastatic human breast cancer. To further elucidate their mechanism of action, we studied several of these compounds using human breast cancer cell lines maintained in long-term tissue culture as a model system. Antiestrogens including tamoxifen (NSC-180973; ICI-46474), nafoxidine. CI-628, and clomiphene citrate inhibit macromolecular synthesis below control levels in two human breast cell lines. This effect is limited to cell lines which contain estrogen receptors. Simultaneous addition of as little as 1000-fold less estradiol prevents antiestrogen effects. Sequential addition of estrogen for up to 48 hours to cells incubated in antiestrogen reverses inhibition. If cells are continued in antiestrogen alone for more than about 3 days, inhibitory effects become irreversible. The cells detach from the surface of the culture vessel and are no longer viable. Tamoxifen competes with 3H-estradiol for specific receptor sites but with about a 100-fold lower apparent affinity. Direct binding of 3H-tamoxifen and 3H-estradiol to duplicate cytoplasmic extracts reveals equivalent numbers of binding sites but a 20-fold lower affinity for the antiestrogen. There is reasonable agreement between concentrations of tamoxifen which bind to receptor and concentrations which inhibit cells.

Entities:  

Keywords:  Biology; Breast Cancer; Cancer; Clinical Research; Clomiphene--side effects; Cytologic Effects; Diseases; Endocrine System; Estradiol--side effects; Estrogens; Examinations And Diagnoses; Family Planning; Fertility Agents; Hormone Antagonists--side effects; Hormone Receptors; Hormones; In Vitro; Laboratory Examinations And Diagnoses; Laboratory Procedures; Membrane Proteins; Nafoxidine--side effects; Neoplasms; Physiology; Reproductive Control Agents; Research Methodology; Tamoxifen--side effects

Mesh:

Substances:

Year:  1976        PMID: 1035504

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

1.  Tamoxifen in the management of metastatic cancer of the breast.

Authors:  L A Cone; N E Romanoff; N A Helm
Journal:  West J Med       Date:  1979-09

2.  Effects of tamoxifen in relation to breast cancer.

Authors:  V C Jordan
Journal:  Br Med J       Date:  1977-06-11

3.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer.

Authors:  M E Lippman; R B Dickson; S Bates; C Knabbe; K Huff; S Swain; M McManaway; D Bronzert; A Kasid; E P Gelmann
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

5.  Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships.

Authors:  K E Allen; E R Clark; V C Jordan
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

Review 6.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 7.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

8.  Effects of tamoxifen on endometrial carcinogenesis in mice.

Authors:  K Niwa; S Morishita; M Hashimoto; T Itoh; J Fujimoto; H Mori; T Tamaya
Journal:  Jpn J Cancer Res       Date:  1998-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.